These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17172428)

  • 1. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
    Mistry SJ; Atweh GF
    Mol Cancer Ther; 2006 Dec; 5(12):3248-57. PubMed ID: 17172428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer.
    Miceli C; Tejada A; Castaneda A; Mistry SJ
    Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.
    Mistry SJ; Bank A; Atweh GF
    Mol Cancer Res; 2007 Aug; 5(8):773-82. PubMed ID: 17670914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
    Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
    Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting stathmin in prostate cancer.
    Mistry SJ; Bank A; Atweh GF
    Mol Cancer Ther; 2005 Dec; 4(12):1821-9. PubMed ID: 16373697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle.
    Iancu C; Mistry SJ; Arkin S; Atweh GF
    Cancer Res; 2000 Jul; 60(13):3537-41. PubMed ID: 10910066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
    Vadgama JV; Wu Y; Shen D; Hsia S; Block J
    Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
    Nomura T; Yamasaki M; Nomura Y; Mimata H
    Oncol Rep; 2005 Oct; 14(4):993-7. PubMed ID: 16142363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
    Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
    Dong YB; Yang HL; Elliott MJ; McMasters KM
    Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
    Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
    Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
    Wigington DP; Urben CM; Strugnell SA; Knutson JC
    Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
    Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
    Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV; Ji M; Bloomer WD
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle.
    Mistry SJ; Benham CJ; Atweh GF
    Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):41-9. PubMed ID: 11258620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
    Dorie MJ; Brown JM
    Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
    Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
    Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer.
    Elliott MJ; Baker JD; Dong YB; Yang HL; Gleason JF; McMasters KM
    Tumour Biol; 2002; 23(6):324-36. PubMed ID: 12677090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.